Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting (Journal of Gastroenterology, (2024), 10.1007/s00535-024-02186-9)

the Japan Oncology Network in Hepatobiliary and Pancreas

Research output: Contribution to journalComment/debate

Abstract

The article ‘Efficacy of liposomal irinotecan + 5‑FU/LV vs. S‑1 in gemcitabine‑refractory metastatic pancreatic cancer: a real‑world study using inverse probability of treatment weighting’, written by ‘Hiroshi Imaoka, Masafumi Ikeda, Satoshi Kobayashi, Akihiro Ohba, Masayuki Ueno, Yuko Suzuki, Hidetaka Tsumura, Nana Kimura, Shinya Kawaguchi, Yasuyuki Kawamoto, Kohei Nakachi, Kunihiro Tsuji, Noritoshi Kobayashi, Reiko Ashida, Naohiro Okano, Kumiko Umemoto, Gou Murohisa, Ayumu Hosokawa, Akinori Asagi, Hiroko Nebiki, Rei Suzuki, Takeshi Terashima, Ryusuke Shibata, Kazuhito Kawata, Toshifumi Doi, Hiroshi Ohyama, Yohei Kitano, Kazuhiko Shioji, Hiroyuki Okuyama, Atsushi Naganuma, Yuji Negoro, Yasunari Sakamoto, Satoshi Shimizu, Chigusa Morizane, Makoto Ueno, Junji Furuse, Hiroaki Nagano, the Japan Oncology Network in Hepatobiliary and Pancreas’, was originally published under exclusive license to Japanese Society of Gastroenterology.

Original languageEnglish
JournalJournal of Gastroenterology
DOIs
StateAccepted/In press - 2025

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting (Journal of Gastroenterology, (2024), 10.1007/s00535-024-02186-9)'. Together they form a unique fingerprint.

Cite this